Natalizumab: A new treatment for relapsing remitting multiple sclerosis

References

• AharoniRTeitelbaumDLeitnerOSpecific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1Proc Natl Acad Sci U S A20009711472711027347
   PubMed Web of Science ®Google Scholar
• AvasaralaJRCrossAHCliffordDBRapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosisMult Scler20039596212617270
   PubMed Web of Science ®Google Scholar
• BaylessKJMeiningerGAScholtzJMOsteopontin is a ligand for the αβ1 integrinJ Cell Sci19981111165749547293
   PubMed Web of Science ®Google Scholar
• BennettDLuddenTShahJThe use of pharmacokinetic (PK) modeling and efficacy data to establish optimal dosing of natalizumab (Antegren™) [abstract]Mult Scler20028suppl 1s61P130
   Google Scholar
• BurklyLCJakubowskiANewmanBMSignaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T-cell proliferationEur J Immunol199121287151718763
   PubMed Web of Science ®Google Scholar
• CalabresiPGiovannoniGConfavreuxCIncidence and clinical significance of antibodies during treatment with natalizumab: 2 year results from AFFIRM and SENTINELNeurology2007in press
   Google Scholar
• CarlosTMSchwartzBRKovachNLVascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cellsBlood199076965701697486
   PubMed Web of Science ®Google Scholar
• ClarkWMucklowJIn PantonRChapmanSGathering and weighing the evidenceMedicines management1998LondonBMJ Books and Pharmaceutical, Pr.5974
   Google Scholar
• CohenBAMikolDDMitoxantrone treatment of multiple sclerosis: safety considerationsNeurology20046312 suppl 6S283215623667
   PubMed Web of Science ®Google Scholar
• DaltonCMMiszkielKABarkerGJEffect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosisJ Neurol20042514071315083284
   PubMed Web of Science ®Google Scholar
• DamleNKAruffoAVascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytesProc Natl Acad Sci U S A199188640371713678
   PubMed Web of Science ®Google Scholar
• ElicesMJOsbornLTakadaYVCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding siteCell199060577841689216
   PubMed Web of Science ®Google Scholar
• FilippiniGMunariLIncorvaiaBInterferons in relapsing remitting multiple sclerosis: a systematic reviewLancet20033615455212598138
   PubMed Web of Science ®Google Scholar
• GalettaSLMarkowitzCLeeAGImmunomodulatory agents for the treatment of relapsing multiple sclerosisArch Intern Med20021622161912390057
   PubMed Web of Science ®Google Scholar
• GhalieRGEdanGLaurentMCardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MSNeurology2002599091312297576
   PubMed Web of Science ®Google Scholar
• GoodmanADRossmanHSBar-OrAGLANCE: a double-blind, randomized, placebo-controlled, parallel-group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis2005Program and abstracts of the American Academy of Neurology 57th Annual MeetingApril 9–16, 2005Miami Beach, Florida Abstract S36.003
   Google Scholar
• [IFNB] IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology199343655618469318
   PubMedGoogle Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol199639285948602746
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trialNeurology1995451268767617181
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med20053533697415947079
   PubMed Web of Science ®Google Scholar
• Langer-GouldAAtlasSWBollenAWProgressive multifocal leukoencephalopathy in a patient treated with natalizumabN Engl J Med20053531716000350
   PubMedGoogle Scholar
• LégerOJPYednockTATannerLHumanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosisHum Antibodies199783169265500
   PubMedGoogle Scholar
• LobbRRHemlerMEThe pathophysiologic role of α4 integrins in vivoJ Clin Invest199494172287525645
   PubMed Web of Science ®Google Scholar
• MillerDHKhanOASheremataWAA controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2003348152312510038
   PubMed Web of Science ®Google Scholar
• [MSIF] Multiple Sclerosis International FederationIntroduction [online]2006 Accessed 9 August 2006. URL: http://www.msif.org/en/ms_the_disease/
   Google Scholar
• MunariLLovatiRBoikoATherapy with glatiramer acetate for multiple sclerosisCochrane Database of Syst Rev20034CD004678
   Google Scholar
• [NMSS] National Multiple Sclerosis SocietyResearch fact sheet [online]2006 Accessed 9 August 2006. URL: http://www.nationalmssociety.org/pdf/research/ResearchFactSheet.pdf
   Google Scholar
• NiinoMBodnerCSimardM-LNatalizumab effects on immune cell responses in multiple sclerosisAnn Neurol2006597485416634035
   PubMed Web of Science ®Google Scholar
• O’ConnorPWGoodmanAKapposLThe safety and tolerability of natalizumab: results from the safety-extension study in patients with multiple sclerosis2006Poster presented at: 58th Annual Meeting of the American Academy of NeurologyApril 1–8, 2006San Diego, California
   Google Scholar
• O’ConnorPWGoodmanAWillmer-HulmeAJRandomized multicenter trial of natalizumab in acute MS relapses. Clinical and MRI effectsNeurology20046220384315184611
   PubMed Web of Science ®Google Scholar
• OsbornLHessionCTizardRDirect expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytesCell1989591203112688898
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200635489991016510744
   PubMed Web of Science ®Google Scholar
• [PRISMS] Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis Study GroupRandomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisLancet199835214985049820297
   PubMedGoogle Scholar
• [PRISMS] Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis GroupPRISMS-4: long-term efficacy of interferon-β-1a in relapsing MSNeurology20015616283611425926
   PubMedGoogle Scholar
• RiceG PAIncorvaiaBMunariLInterferon in relapsing-remitting multiple sclerosisCochrane Database Syst Rev20014 CD002002
   Google Scholar
• RudickRAHutchinsonMO’ConnorPNatalizumab improves health-related quality of life in patients with relapsing multiple sclerosisNeurology200666suppl 2A3812
   Google Scholar
• RudickRASandrockANatalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MSExpert Rev Neurotherapeutics2004457180
   PubMedGoogle Scholar
• RudickRAStuartWHCalabresiPAA randomized, placebo-controlled trial of natalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med20063549112316510745
   PubMed Web of Science ®Google Scholar
• SheremataWAVollmerTLStoneLAA safety and pharmacokinetic study of intravenous natalizumab in patients with MSNeurology1999521072410102433
   PubMed Web of Science ®Google Scholar
• TubridyNBehanPOCapildeoRThe effect of anti-α4 integrin antibody on brain lesion activity in MSNeurology1999534667210449105
   PubMed Web of Science ®Google Scholar
• [Tysabri PI] Biogen Idec, Inc.Tysabri® (natalizumab) package insert2006Cambridge, MABiogen Idec, Inc.
   Google Scholar
• Van AsscheGVan RanstMSciotRProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med2006353362815947080
   PubMedGoogle Scholar
• VollmerTLPhillipsJTGoodmanADAn open-label safety and drug interaction study of natalizumab (Antegren™) in combination with interferon-beta (Avonex®) in patients with multiple sclerosisMult Scler2004105112015471366
   PubMed Web of Science ®Google Scholar
• WareJESherbourneCDThe MOS 36-item Short-Form Health Survey (SF-36). Conceptual framework and item selectionMed Care19926473831593914
   PubMedGoogle Scholar
• YousryTAMajorERyschkewitschCEvaluation for progressive multifocal leukoencephalopathy in natalizumab treated patientsN Engl J Med20063549243316510746
   PubMed Web of Science ®Google Scholar